PERBELLINI, RICCARDO
PERBELLINI, RICCARDO
Universita' degli Studi di MILANO
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors
2025 N. Zignani, A. Costantino, M. Sagasta, C. Dibenedetto, R. Perbellini, S.C. UCEDA RENTERIA, P. Lampertico, M. Francesca Donato
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta
2024 E. Degasperi, C. Scholtes, B. Testoni, S.U. Renteria, M.P. Anolli, C. Charre, F. Facchetti, M. Plissonnier, D. Sambarino, R. Perbellini, S. Monico, A. Callegaro, E. García-Pras, S. Lens, M.F. Cortese, X. Forns, S. Pérez-Del-Pulgar, M. Heil, M. Levrero, F. Zoulim, P. Lampertico
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide
2024 P. Toniutto, E. Falleti, S. Cmet, A. Cussigh, E. Degasperi, M.P. Anolli, D. Sambarino, F. Facchetti, M. Borghi, R. Perbellini, S. Monico, P. Lampertico
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis
2022 A. Loglio, P. Ferenci, S.C. UCEDA RENTERIA, C. Tham, C. Scholtes, H. Holzmann, F. van Bömmel, M. Borghi, R. Perbellini, A. Rimondi, E. Farina, E. Trombetta, M. Manunta, L. Porretti, D. Prati, F. Ceriotti, F. Zoulim, A. Bertoletti, P. Lampertico
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
2022 R. D'Ambrosio, E. Degasperi, M. Anolli, I. Fanetti, M. Borghi, R. Soffredini, M. Iavarone, G. Tosetti, R. Perbellini, A. Sangiovanni, V. Sypsa, P. Lampertico
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
The relationship between liver histology and thyroid function tests in patients with nonalcoholic fatty liver disease (NAFLD)
2021 R. D'Ambrosio, I. Campi, M. Maggioni, R. Perbellini, E. Giammona, R. Stucchi, M. Borghi, E. Degasperi, A. De Silvestri, L. Persani, L. Fugazzola, P. Lampertico
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C
2021 S. Varchetta, D. Mele, R. D'Ambrosio, R. Perbellini, A. Lombardi, A. Rojas, S. Paolucci, F. Baldanti, B. Oliviero, S. Mantovani, C. Tinelli, A. De Silvestri, M. Romero Gomez, P. Lampertico, M.U. Mondelli
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting
2021 M. Fabbiani, A. Lombardi, M. Colaneri, P. Del Poggio, P. Perini, R. D'Ambrosio, E. Degasperi, C. Dibenedetto, A. Giorgini, L. Pasulo, F. Maggiolo, F. Castelli, P. Brambilla, O. Spinelli, T. Re, A. Lleo, M. Rumi, C. Uberti-Foppa, A. Soria, A. Aghemo, P. Lampertico, C. Baiguera, M. Schiavini, S. Fagiuoli, R. Bruno, M. Borghi, R. Soffredini, R. Perbellini, A. Gori, V. Ferroni, M. Colpani, M. Manini, G. Cologni, S. Lazzaroni, M. Vinci, S. De Nicola, C. Mazzarelli, T. Angelini Zucchetti, V. Picciotto, M. Puoti, R. Rossotti, S. Landonio, C.F. Magni, G. Rizzardini, E. Colella, P. Columpsi, A. Gambaro, A. Spolti, C. Magnani, P. Vigano, M. Mena, M. Villa, I. Caramma, C. Basilico, F. Capelli, S. Biagiotti, A. Mazzone, V. Saladino, M.P. Baldacci, F. Gatti, L. Varalli, L. Morini, B. Menzaghi, M. Farinazzo, R. Meli, M.C. Plaz Torres, M. Rumi, I. Fanetti, C. Dibenedetto, D. Orellana, P. Zermiani, M. Zuin, A. De Bona, A. D'Arminio Monforte, A. Capretti, M.T. Taddei, M. Soncini, A. Spinetti, S. Zaltron, M.G. Pigozzi, A. Rossini, A. Pan, S. Dal Zoppo, A. Zoncada, M. Memoli, S. Salpietro, H. Hamid, E. Messina, A.E. Colombo, O. Giglio, P. Bonfanti, C. Molteni, N. Terreni, G. Spinzi, S. Conforti, E. Clerici, F. Menozzi, E. Buscarini, R. Centenaro, A. Corbellini, F. Noventa, S. Gritti, P. Giani
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients
2020 M. Viganò, A. Loglio, F. Cerini, E. Farina, F. Facchetti, R. Perbellini, M.G. Rumi, P. Lampertico
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy
2020 A. Loglio, M. Iavarone, F. Facchetti, D. Di Paolo, R. Perbellini, G. Lunghi, F. Ceriotti, C. Galli, M.T. Sandri, M. Vigano, A. Sangiovanni, M. Colombo, P. Lampertico
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs
2020 E. Degasperi, E. Galmozzi, S. Pelusi, R. D'Ambrosio, R. Soffredini, M. Borghi, R. Perbellini, F. Facchetti, M. Iavarone, A. Sangiovanni, L. Valenti, P. Lampertico
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis : a case report of 3 patients
2019 A. Loglio, P. Ferenci, S.C. Uceda Renteria, C.Y.L. Tham, F. van Bommel, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Greco, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Bertoletti, P. Lampertico
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
2018 E. Degasperi, A. Aghemo, S. Paolucci, R. D'Ambrosio, M. Borghi, R. Perbellini, F. Novazzi, S. De Nicola, G. Lunghi, F. Baldanti, P. Lampertico
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression
2018 R. D'Ambrosio, A. Aghemo, M.G. Rumi, E. Degasperi, A. Sangiovanni, M. Maggioni, M. Fraquelli, R. Perbellini, W. Rosenberg, P. Bedossa, M. Colombo, P. Lampertico
I MICRORNA NELLE DISTROFIE MIOTONICHE
2010 R. Perbellini
Determination of urinary 2,5-hexanedione in the general Italian population
1998 P. Bavazzano, P. Apostoli, C. Balducci, G.B. Bartolucci, M. Buratti, P. Duca, G. Gori, V. Li Donni, L. Perbellini, A. Perico, C. Minoia